The Expanding Role of Immunotherapy for the Treatment of Multiple Myeloma - Focus on Antibodies, Antibody-Drug Conjugates, and CAR T-Cells
Release Date: August 3, 2020
Expiration Date: August 3, 2021
Watch the experts who are actively engaged in the care of patients with multiple myeloma.
The target audience for this activity is community and academic hematologists, medical onoclogists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.
After participating in this activity, participants should be better able to:
- Review unmet needs in the care of multiple myeloma (MM) and the potential role of immunotherapeis such as antibodies, antibody-drug conjugates, CAR T-cells, and others
- Evaluate clinical trial data of current and emerging immunotherapies being examined in patients with MM
- Assess unique adverse event profiles of immunotherapies that differ from traditional therapies used for the treatment of patients with MM
- Develop strategies to integrate immunotherapies into the MM treatment paradigm as they become available
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality. All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
This activity is supported by independent educational grants from Legend Biotech and Sanofi Genzyme
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.